NCT01626495View on ClinicalTrials.gov

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 17, 2011

Primary Completion Date

May 7, 2018

Study Completion Date

July 11, 2019

Conditions
B Cell LeukemiaB Cell Lymphoma
Interventions
BIOLOGICAL

CART-19

Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.

Trial Locations (1)

19104

CHOP - http://www.chop.edu/service/oncology/pediatric-cancer-research/cart-19-trial.html, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT01626495 - Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma | Biotech Hunter | Biotech Hunter